Scientists probe hidden clues to immunotherapy success in endometrial cancer

NCT ID NCT07690540

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features. The goal is to discover new biomarkers that can better predict who will benefit from treatment, beyond current tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could identify new biomarkers to predict which patients will benefit from immunotherapy, improving treatment decisions and outcomes.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • European Institute of Oncology

    RECRUITING

    Milan, Italy, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.